Please login to the form below

Not currently logged in
Email:
Password:

sunitinib

This page shows the latest sunitinib news and features for those working in and with pharma, biotech and healthcare.

EU approval for Opdivo combo in renal cell cancer

EU approval for Opdivo combo in renal cell cancer

The CheckMate -214 trial showed the combination was superior to current standard, Pfizer’s Sutent (sunitinib), in extending overall survival, though data was limited to a subset of patients with intermediate ... Median OS in patients treated

Latest news

More from news
Approximately 2 fully matching, plus 61 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

    In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the  CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate

  • Oncology drugs under AMNOG

    Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics